Medivir AB (publ) (MVRBF) and Its Competitors Critical Survey

Medivir AB (publ) (OTCMKTS:MVRBF – Get Free Report) is one of 386 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Medivir AB (publ) to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, valuation, risk and earnings.

Insider and Institutional Ownership

23.2% of Medivir AB (publ) shares are held by institutional investors. Comparatively, 24.3% of shares of all “Biotechnology” companies are held by institutional investors. 24.5% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Get Medivir AB (publ) alerts:

Analyst Ratings

This is a summary of recent recommendations for Medivir AB (publ) and its rivals, as reported by MarketBeat.com.

Medivir AB (publ) currently has a consensus target price of $50.00, indicating a potential upside of 5,997.56%. As a group, “Biotechnology” companies have a potential upside of 94.71%. Given Medivir AB (publ)’s stronger consensus rating and higher probable upside, analysts plainly believe Medivir AB (publ) is more favorable than its rivals.

Profitability

This table compares Medivir AB (publ) and its rivals’ net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Medivir AB (publ) and its rivals revenue, earnings per share and valuation.

Medivir AB (publ)’s rivals have higher revenue and earnings than Medivir AB (publ). Medivir AB (publ) is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Medivir AB (publ) beats its rivals on 7 of the 11 factors compared.

About Medivir AB (publ)

(Get Free Report)

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

Receive News & Ratings for Medivir AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivir AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.